Ming-Fen Ho

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
M.-f. Ho, Ming-fen Ho, Ming‐fen Ho
Publication record
40 papers · 396 citations · H-index 14

PAPERS

Biomarker for craving and acamprosate treatment response in patients with alcohol use disorder: insights from multi-omics.
20260 citationsauthor #1
Plasma TREM2 levels, alcohol consumption, and liver enzymes in patients with alcohol use disorder: a sex-dependent relationship involving MS4A6A genetic polymorphism.
20251 citationsauthor #1
The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention
20255 citationsauthor #6
Buprenorphine's Effect on the Human Immune System and Inflammation
20250 citationsauthor #5
Molecular mechanisms involved in alcohol craving, IRF3, and endoplasmic reticulum stress: a multi-omics study
20244 citationsauthor #1
IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study
20244 citationsauthor #1
Androgen receptor-mediated pharmacogenomic expression quantitative trait loci: implications for breast cancer response to AR-targeting therapy
20241 citationsauthor #6
Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation
20238 citationsauthor #1
Corrigendum to “Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder” [Drug Alcohol Depend. 243 (2023) 109753]
20230 citationsauthor #13
Single cell transcriptomics reveals distinct transcriptional responses to oxycodone and buprenorphine by iPSC-derived brain organoids from patients with opioid use disorder
202224 citationsauthor #1
Plasma TNFSF10 levels associated with acamprosate treatment response in patients with alcohol use disorder
20228 citationsauthor #1
ACE2 and TMPRSS2 SARS-CoV-2 infectivity genes: deep mutational scanning and characterization of missense variants
20227 citationsauthor #4
Genetic predisposition to major depressive disorder differentially impacts alcohol consumption and high-risk drinking situations in men and women with alcohol use disorder.
20222 citationsauthor #13
Genetic variants associated with acamprosate treatment response in alcohol use disorder patients: A multiple omics study
202212 citationsauthor #1
P55. TRAIL Protein Levels are Associated With Response to Acamprosate Therapy in Alcohol Use Disorder: A Proteomics-Based Approach
20220 citationsauthor #17
Genome-wide association study for circulating FGF21 in patients with alcohol use disorder: Molecular links between the SNHG16 locus and catecholamine metabolism
202217 citationsauthor #1
P5. Single Cell Transcriptomics Reveals Distinct Transcriptional Response to Oxycodone and Buprenorphine by iPSC-Derived Brain Organoids From Patients With Opioid Use Disorder
20221 citationsauthor #1
SLCO1B1: Application and Limitations of Deep Mutational Scanning for Genomic Missense Variant Function
202119 citationsauthor #3
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study
202133 citationsauthor #12
Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction
202118 citationsauthor #3
TSPAN5 Regulates Serotonin and Kynurenine Levels: Pharmacogenomic Mechanisms Related to Alcohol Use Disorder and Acamprosate Treatment Response
20200 citationsauthor #1
TSPAN5 influences serotonin and kynurenine: pharmacogenomic mechanisms related to alcohol use disorder and acamprosate treatment response
202022 citationsauthor #1
Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in CYP2C9 and CYP2C19
201920 citationsauthor #3
Catechol O‐Methyltransferase Pharmacogenomics: Challenges and Opportunities
20194 citationsauthor #1
Ketamine and Active Ketamine Metabolites Regulate STAT3 and the Type I Interferon Pathway in Human Microglia: Molecular Mechanisms Linked to the Antidepressant Effects of Ketamine
201939 citationsauthor #1
T130. Transcriptome Profile in iPSC-Derived Astrocytes of TCF7L2, a Transcription Factor Associated With Bipolar Disorder, Reveals Relationship With Neural Function
20190 citationsauthor #8
Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression
201845 citationsauthor #1
TCL1A, a Novel Transcription Factor and a Coregulator of Nuclear Factor κB p65: Single Nucleotide Polymorphism and Estrogen Dependence
20187 citationsauthor #1
Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes
201714 citationsauthor #2
TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88–Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism– and Selective Estrogen Receptor Modulator–Dependent Modification of Inflammation and Immune Response
201717 citationsauthor #1
Immune Mediator Pharmacogenomics: TCL1A SNPs and Estrogen-Dependent Regulation of Inflammation.
20173 citationsauthor #1
Pharmacology of the Adenosine A3 Receptor in the Vasculature and Essential Hypertension
201621 citationsauthor #1
Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation.
201626 citationsauthor #1
Abstract LB-191: Association of anti-estrogen therapy in breast cancer patients and subsequent risk of rheumatoid arthritis: An electronic health record study
20150 citationsauthor #2
THU0481 Aromatase Inhibitor Treatment and Musculoskeletal Adverse Events: SNP Modulated, Estrogen-Dependent Variation in Ccr6/Ccl20 Expression
20141 citationsauthor #1
OP0193 The Rheumatoid Arthritis -Risk Locus CCR6 and Its Snp-Dependent Response to Estrogen: A Possible Genomic Link between Sex Hormones and the IL-17 Inflammatory Pathway
20141 citationsauthor #1
Vascular adenosine receptors; potential clinical applications.
201315 citationsauthor #1
L-002 ADENOSINE A2a RECEPTOR GENE EXPRESSION IN ESSENTIAL HYPERTENSION
20110 citationsauthor #1
An investigation of an ATP-binding cassette gene variant and susceptibility to essential hypertension
20080 citationsauthor #1
Acamprosate—an Anti-Craving Drug for Alcohol Use Disorder (AUD) Pharmacotherapy: Plasma Metabolomics Signatures are Associated With Alcohol Craving Intensity and Acamprosate Treatment Response
year unknown0 citationsauthor #1

TIMELINE

2008 0 citations

2011 0 citations

2013 15 citations

2014 2 citations

2015 0 citations

2016 47 citations

2017 34 citations

2018 52 citations

2019 63 citations

2020 22 citations

2021 70 citations

2022 71 citations

2023 8 citations

2024 9 citations

2025 6 citations

2026 0 citations

Unknown 0 citations

Ming-Fen Ho

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT